Efficacy and Tolerability of Losartan in Patients with Essential Hypertension: a Multicentre, Double-Blind Comparison of Losartan with Metoprolol

Journal of Clinical and Basic Cardiology

Kanic V¹  Soucek M¹  Dobovisek J¹  Rekic S¹  Spinar J¹  Niegowska J¹ 

[1] $$

关键词: Hypertonie;    Kardiologie;    Losartan;    Metoprolol;    cardiology;    hypertension;    Losartan;    Metoprolol;   

DOI  :  

学科分类：心脏病和心血管学

来源: Krause & Pachernegg GmbH

【 摘 要 】

A multicentre, randomised, double-blind, comparative study of antihypertensive efficacy and safety of losartan and metoprolol was carried out in77 patients with mild to moderate essential hypertension. Normalisation of sitting diastolic blood pressure (siDBP) and sitting systolic bloodpressure (siSBP) at the end of the study was considered as the primary criterion for evaluation. A decrease of siDBP for at least 10 % and that ofsiSBP for at least 15 % was considered as response to treatment. After 2 weeks of single placebo run-in period the patients were randomised to either losartan 50 to 100 mg od or metoprolol 50 to 100 mg bid. After 3 weeks of the treatment the initial dose of both drugs was doubled if target siDBP was not achieved. After 6 weeks of monotherapy hydrochlorothiazide 12.5 mg was added for the last 3 weeks if necessary.Losartan and metoprolol significantly reduced siSBP and siDBP versus baseline: –20.8/15.9 mmHg and –16.2/16.6 mmHg, respectively (allp < 0.001). There was no significant difference between the treatment regimens found during the study in regard to siSBP and siDBP decrease.In the losartan arm the primary criterion for efficacy was achieved in 72.3 % for both siSBP and siDBP. In patients treated with metoprolol theseresults were 63.0 and 85.2 %, respectively (n.s.). No significant differences between treatment regimens were observed in regard to completenormalisation of blood pressure (< 140/90 mmHg in single patient) and overall blood pressure response. In both groups heart rate decreasedsignificantly and similarly. Both treatments were well tolerated. Adverse events were reported by 16.3 % of patients treated with losartan and 21.4% of patients treated with metoprolol (n.s.). There were no serious adverse events.Conclusion: In this study in patients with mild to moderate essential hypertension, losartan in comparison with metoprolol exerted substantial andcomparable antihypertensive efficacy, as well as a similar safety profile.

【 授权许可】

Unknown